How The Mixed Analyst Calls Are Reframing The Cardinal Health (CAH) Investment Story
Find your next quality investment with Simply Wall St’s easy and powerful screener, trusted by over 7 million individual investors worldwide.
Cardinal Health is back in focus as fresh Street research reshapes the price target conversation, with several firms trimming their targets while one raises its view and another starts coverage on a bullish footing. Those mixed calls reflect a split between analysts who see room for upside if execution holds and others who are more cautious about how much to pay for the stock right now. As you read on, you will see how to track these shifting views and what they might mean for your own decision making around Cardinal Health.
What Wall Street Has Been Saying
🐂 Bullish Takeaways
-
TD Cowen lifted its price target by US$4 in early May, which signals some confidence in Cardinal Health’s execution and the potential for the current setup to support a higher valuation.
-
William Blair recently initiated coverage with a bullish stance, highlighting that, at current levels, the stock may offer an appealing entry point if the company delivers on its growth and margin plans.
🐻 Bearish Takeaways
-
Several firms, including JPMorgan, Baird, Citi, BofA, and Evercore ISI, have all trimmed their price targets in recent weeks, which points to increased caution on how much investors should be willing to pay for the stock right now.
-
The cluster of reductions, ranging from US$4 to US$28 and US$20 cuts by large houses like JPMorgan and Evercore ISI, suggests some analysts are reassessing the risk reward balance around Cardinal Health’s execution and longer term growth profile.
Do your thoughts align with the Bull or Bear Analysts? Perhaps you think there’s more to the story. Head to the Simply Wall St Community to discover more perspectives!
We’ve flagged 2 risks for Cardinal Health. See which could impact your investment.
What’s in the News
-
Cardinal Health reported Q3 fiscal 2026 adjusted EPS of US$3.17, more than 13% above analyst estimates, on revenue of US$60.94b that was 11% higher year over year and about 2.1% below market expectations, while raising full year adjusted EPS and adjusted free cash flow guidance and recording an 18% increase in non GAAP operating earnings plus a US$184m goodwill impairment tied to the Navista business.
-
The company repurchased US$250m of stock in Q3, taking total fiscal 2026 buybacks to US$1.0b and completing the repurchase of 11,719,964 shares, or 4.87%, under the program announced on June 8, 2023.
-
Cardinal Health declared a quarterly dividend of US$0.5158 per share, payable on July 15, 2026, with an ex dividend and record date of July 1, 2026.
-
The company is expanding Actinium 225 production at its Center for Theranostics Advancement in Indianapolis, adding a high capacity line that substantially increases cGMP compliant output and supports more than 15 clinical trials, and separately issued a voluntary recall of select Webcol Large Alcohol Prep Pad lots in the U.S., Puerto Rico, and Japan due to microbial contamination concerns.
